{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:35:56Z","timestamp":1780504556603,"version":"3.54.1"},"reference-count":15,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Autoimmune thrombocytopenia is a common manifestation of systemic lupus erythematosus (SLE). Its main treatments are glucocorticoids, intravenous immunoglobulin, and immunosuppressants, but thrombopoietin mimetics may be considered with refractory to conventional treatment. Romiplostim, a thrombopoietin receptor agonist, has been approved for increasing platelet counts in corticosteroid-refractory chronic immune thrombocytopenia. However, data on its long-term safety and efficacy in patients with SLE are still lacking. Case Presentation: We present the case of a 55-year-old woman with SLE and refractory immune thrombocytopenia who developed bilateral adrenal hemorrhage and progressed to fatal catastrophic anti-phospholipid syndrome while using romiplostim.<\/jats:p>","DOI":"10.3390\/jcm14093091","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:50:17Z","timestamp":1745992217000},"page":"3091","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Systemic Lupus Erythematosus with Refractory Immune Thrombocytopenia Progressing to Catastrophic Anti-Phospholipid Syndrome During Thrombopoietin Receptor Agonist Therapy: A Case Report"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3449-696X","authenticated-orcid":false,"given":"Sang Wan","family":"Chung","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul 02447, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-9523","authenticated-orcid":false,"given":"You-Jung","family":"Ha","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea"},{"name":"Department of Internal Medicine, Seoul University College of Medicine, Seoul 03080, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e000078","DOI":"10.1136\/lupus-2014-000078","article-title":"Haematological manifestations of lupus","volume":"2","author":"Fayyaz","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/rheumatology\/keg069","article-title":"Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems","volume":"42","author":"Sultan","year":"2003","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.31138\/mjr.28.1.20","article-title":"Lupus thrombocytopenia: Pathogenesis and therapeutic implications","volume":"28","author":"Galanopoulos","year":"2017","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","first-page":"99","article-title":"Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia","volume":"7","author":"Vishnu","year":"2016","journal-title":"J. Blood Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/key119","article-title":"Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists","volume":"57","author":"Guitton","year":"2018","journal-title":"Rheumatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.semarthrit.2015.07.008","article-title":"Two cases of thrombosis in patients with anti-phospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist","volume":"45","author":"LaMoreaux","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0961203313499959","article-title":"Immune thrombocytopaenic purpura: An autoimmune cross-link between infections and vaccines","volume":"23","author":"Rinaldi","year":"2014","journal-title":"Lupus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0961203314559632","article-title":"Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus","volume":"24","author":"Maroun","year":"2015","journal-title":"Lupus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00005792-200303000-00005","article-title":"Adrenal involvement in the anti-phospholipid syndrome: Clinical and immunologic characteristics of 86 patients","volume":"82","author":"Espinosa","year":"2003","journal-title":"Medicine"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Jacobs, L., Wauters, N., Lablad, Y., Morelle, J., and Taghavi, M. (2024). Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Antibodies, 13.","DOI":"10.3390\/antib13010021"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/0961203313477900","article-title":"Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim","volume":"22","author":"Tomov","year":"2013","journal-title":"Lupus"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3091\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:24:26Z","timestamp":1760030666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14093091"],"URL":"https:\/\/doi.org\/10.3390\/jcm14093091","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}